The antiviral drug tecovirimat (Tpoxx, SIGA Technologies) did not reduce the duration of mpox lesions among children and adults with clade I mpox in the Democratic Republic of the Congo (DRC), based on an early analysis of data from the PALM007 trial.
However, study participants saw a 1.7% overall mortality, regardless of whether they received the drug, which was much lower than the mpox mortality rate of 3.6% or higher reported among all cases in the DRC. The study